Trial reportBMC medicine2025
Efficacy and safety of Janus kinase 1/2 inhibitor KL130008 in active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase II trial.
Trial report in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKL130008 is a selective Janus kinase 1/2 inhibitor with encouraging preclinical efficacy. Phase I trials in healthy volunteers and patients with rheumatoid arthritis (RA) showed favorable pharmacokinetics, dose-dependent inhibition of phosphorylated signal transducer and activator of transcription 3, good tolerability, and no clinically meaningful pharmacokinetic interaction with methotrexate, supporting further evaluation in active RA.
methodsIn this double-blind, placebo-controlled phase II trial at 24 centers in China, RA patients were randomized (1:1:1:1) to receive placebo or KL130008 capsules (0.5, 1 or 2 mg) once daily for 12 weeks. Week 13-24, the placebo group was switched 1:1 to KL130008 at 0.5 mg or 1 mg, while other groups continued their original doses. All patients received 7.5-25 mg methotrexate once weekly throughout 24 weeks. The primary outcome was the proportion of patients who achieved at least 20% improvement in American College of Rheumatology criteria (ACR20) after 12 weeks of treatment. Secondary outcomes included ACR50/70 responses, Disease Activity Score 28 (DAS28) changes, safety assessments and pharmacokinetic properties.
resultsBy week 12, the proportion of patients achieving ACR20 was significantly lower in the placebo group (26.8%) than in the groups receiving KL130008 at 1 mg (55.0%, p = 0.011) or 2 mg (64.1%, p = 0.001). KL130008 at 2 mg also significantly outperformed placebo for ACR50 or ACR70 responses, DAS28-C-reactive protein, DAS28- erythrocyte sedimentation rate, and the Health Assessment Questionnaire Disability Index scores. The clinical benefits of KL130008 persisted through week 24 and were associated with markedly lower levels of tumor necrosis factor-a and interleukin-6 in blood, without affecting levels of interleukin-15. The oral drug showed linear pharmacokinetics and mild accumulation. During the 24-week treatment, drug-related treatment-emergent adverse events occurred in approximately half of the patients receiving KL130008 (52.5%, 50.0%, and 56.4% in the 0.5, 1, and 2 mg groups), and the most frequent events were anemia and hyperlipidemia.
conclusionsKL130008 demonstrated potential for sustained efficacy and safety in the treatment of RA.
trial registrationRegistered in the Chinese Clinical Trial Register (ChiCTR2100042141).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.